Panel wants FDA to approve Xarelto as preventive stroke therapy

An FDA advisory panel endorsed the approval of anticoagulant Xarelto to prevent stroke in patients with atrial fibrillation. Earlier, agency staff questioned whether Xarelto is superior to standard drug warfarin. Xarelto developers Johnson & Johnson and Bayer expect an FDA decision in November.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA